The relapse rate for children with acute myeloid leukemia (AML) remains high despite advancements in risk classification, multi-agent chemotherapy intensification, stem cell transplantation, and supportive care guidelines
The relapse rate for children with acute myeloid leukemia (AML) remains high despite advancements in risk classification, multi-agent chemotherapy intensification, stem cell transplantation, and supportive care guidelines. these scholarly studies, GO again earned Food and Drug Administration (FDA) approval in 2017 for the treatment of newly diagnosed CD33-positive AML in r/r adults and children 2 … [Read more…]